Treatment with lumasiran improved kidney outcomes in patients with primary hyperoxaluria type 1, with no cases of end-stage kidney disease observed during follow-up in a study presented at Kidney Week....
In a qualitative study of physicians managing patients with primary hyperoxaluria type 1 (PH1), presented at Kidney Week 2025, clinicians emphasized simplicity, patient convenience, and ease of...
In a large real-world cohort study comparing semaglutide with metformin, investigators found no significant difference in the risk of incident urinary stone disease. Despite meaningful reductions in BMI...
